Global pioneers in hypoxia inducible factor (HIF) biology.
Dedicated to advancing care for serious diseases.
We were founded in 2007 to discover and develop therapeutic solutions leveraging the potential of hypoxia inducible factor—or HIF—biology. We believe HIF-Prolyl Hydroxylase (HIF-PH) inhibition could represent an approach to treating certain conditions where there is unmet need.
Our objective is to develop and commercialize these products, starting with our lead compound, vadadustat, an investigational product being studied in patients with anemia secondary to chronic kidney disease (CKD). We intend to:
- Complete the development of vadadustat for anemia secondary to CKD.
- Obtain regulatory approval of vadadustat for anemia secondary to CKD in the US, Europe, and other markets.
- Upon approval by the FDA, commercialize vadadustat in the United States, in partnership with Otsuka, and collaborate in other territories.
- Advance pipeline assets.
- Acquire or in-license additional nephrology products.
Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.